Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: GlobalData | PRODUCT CODE: 1893733

Cover Image

PUBLISHER: GlobalData | PRODUCT CODE: 1893733

Insomnia: Opportunity Assessment and Forecast Update

PUBLISHED:
PAGES: 72 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
ZIP (Single User License)
USD 17995
ZIP (Site License)
USD 35990
ZIP (Global License)
USD 53985

Add to Cart

This report covers the 7MM and provides an Excel-based forecast model for the Insomnia market through 2032.

Z-drugs are the most common first-line treatment for insomnia across the US and 5EU. The insomnia pipeline in the 7MM is sparse but varied, containing products with varying mechanisms of action. There are five pipeline products in Phase II and III stages of clinical development for insomnia. The insomnia market across the 7MM was valued at $3.1 billion in the 2022 baseline year. Over the 10- year forecast period, the market is projected to grow at a compound annual growth rate (CAGR) of 2.1%, reaching $3.8 billion by 2032. The entry of the two pipeline products during the forecast period will have a significant impact on the market. They are anticipated to contribute $288 million in sales by 2032.

Scope

  • Overview of insomnia market, including epidemiology, symptoms, diagnosis, and disease management.
  • Annualized insomnia therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2022 to 2032.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the insomnia market.
  • Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for insomnia. The most promising candidates in late-stage development are profiled.
  • Analysis of the current and future market competition in the 7MM insomnia therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the 7MM insomnia therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the insomnia therapeutics market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Product Code: GDHCOA061

Table of Contents

Table of Contents

1. Preface

  • 1.1. Contents
  • 1.2. Abbreviations
  • 1.3. Related Reports

2. Executive Summary

  • 2.1. Summary of Updates

3. Disease Overview

  • 3.1. Overview of Insomnia
  • 3.2. Insomnia SWOT Analysis
  • 3.3. Pathophysiology of Insomnia
  • 3.4. Classification of Insomnia

4. Epidemiology

  • 4.1. Total Prevalent Cases of Insomnia, Both Sexes, Ages >=15 Years, 2022-32
  • 4.2. Age-Specific Trends in the Total Prevalent Cases of Insomnia, Both Sexes, 2022
  • 4.3. Sex-Specific Total Prevalent Cases of Insomnia, Both Sexes, Ages >=15 Years, 2022
  • 4.4. Sex-Specific Total Prevalent Cases of Acute Insomnia, Ages >=15 Years, 2022
  • 4.5. Sex-Specific Total Prevalent Cases of Chronic Insomnia, Ages >=15 Years, 2022
  • 4.6. Sources and Methodology for Acute and Chronic Insomnia Prevalence
  • 4.7. Sources and Methodology - Total Prevalent Cases of Acute and Chronic Insomnia

5. Current Treatment Options

  • 5.1. Treatment Paradigm
  • 5.2. Current Treatment Options
  • 5.3. Product Profile: Benzodiazepines (e.g., estazolam, temazepam, flurazepam)
  • 5.4. Product Profile: Z-Drugs (zaleplon, zolpidem, zopiclone, eszopiclone)
  • 5.5. Product Profile: Melatonin Receptor Agonists (ramelteon and melatonin ER)
  • 5.6. Product Profile: Low-Dose Antidepressants (doxepin, trazodone, trimipramine)
  • 5.7. Product Profile: Antihistamines (e.g., diphenhydramine, promethazine, hydroxyzine)
  • 5.8. Product Profile: Gabapentinoids (e.g., gabapentin and pregabalin)
  • 5.9. Product Profile: Merck & Co's Belsomra (suvorexant)
  • 5.10. Product Profile: Eisai's Dayvigo (lemborexant)
  • 5.11. Product Profile: Idorsia's Quviviq (daridorexant)
  • 5.12. Product Profile: Taisho Pharmaceutical's Borzi (vornorexant)
  • 5.13. Patient Flow: Insomnia in 2022 Across 7MM

6. Unmet Needs and Opportunities

  • 6.1. Unmet Needs in Insomnia
  • 6.2. New Therapeutic Options with Improved Efficacy
  • 6.3. Improved Physician Awareness of Insomnia Treatments
  • 6.4. Improved Patient Access to CBT-i

7. R&D Strategies

  • 7.1. Trends in Clinical Trial Design in Insomnia
  • 7.2. Trends in Deal-Making in Insomnia

8. Pipeline Assessment

  • 8.1. Insomnia Pipeline Overview
  • 8.2. Late-Stage Pipeline Agents for Insomnia
  • 8.3. Product Profile: EUSOL Biotech's SM-1
  • 8.4. Product Profile: Imbrium Therapeutics's Sunobinop
  • 8.5. Product Profile: Vanda Pharmaceuticals's Hetlioz (tasimelteon)
  • 8.6. Insomnia: Clinical Trials (Phase II/III) Overview

9. Market Outlook

  • 9.1. Insomnia Market Forecast
  • 9.2. Market Drivers and Barriers

10. Appendix

  • 10.1. Primary Research: KOL Information
  • 10.2. Primary Research: High-Prescriber Survey Information
  • 10.3. Bibliography
  • 10.4. About the Authors

11. Contact Us

Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!